Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
ASRT 
Assertio Therapeutics Inc (ASRT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/26/2025: ASRT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $39.94
1 Year Target Price $39.94
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -2.98% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/26/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 63.78M USD | Price to earnings Ratio - | 1Y Target Price 39.94 |
Price to earnings Ratio - | 1Y Target Price 39.94 | ||
Volume (30-day avg) 4 | Beta 0.56 | 52 Weeks Range 7.71 - 15.15 | Updated Date 12/28/2025 |
52 Weeks Range 7.71 - 15.15 | Updated Date 12/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.5 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -21.06% | Operating Margin (TTM) 28.72% |
Management Effectiveness
Return on Assets (TTM) -4.17% | Return on Equity (TTM) -24.48% |
Valuation
Trailing PE - | Forward PE 13.24 | Enterprise Value 10284041 | Price to Sales(TTM) 0.46 |
Enterprise Value 10284041 | Price to Sales(TTM) 0.46 | ||
Enterprise Value to Revenue 0.07 | Enterprise Value to EBITDA 2.27 | Shares Outstanding 6416805 | Shares Floating 5709035 |
Shares Outstanding 6416805 | Shares Floating 5709035 | ||
Percent Insiders 6.28 | Percent Institutions 27.28 |
Upturn AI SWOT
Assertio Therapeutics Inc
Company Overview
History and Background
Assertio Therapeutics Inc. (formerly Depomed, Inc.) was founded in 1995. It was a biopharmaceutical company focused on developing and commercializing products for pain management and neurological disorders. In 2013, the company underwent a strategic shift, acquiring a portfolio of products from Depomed, Inc. and subsequently rebranding as Assertio Therapeutics in 2018. This move aimed to diversify its product offerings and revenue streams beyond its initial focus. The company has since continued to evolve its strategy, focusing on its marketed products and exploring new growth avenues.
Core Business Areas
- Specialty Pharmaceuticals: Assertio Therapeutics focuses on the commercialization and marketing of its existing portfolio of branded pharmaceutical products, primarily in the areas of pain management and neurology. They leverage their sales and marketing infrastructure to drive sales of these established medications.
Leadership and Structure
Assertio Therapeutics operates with a typical corporate structure led by a Board of Directors and a senior management team. Key leadership positions include a Chief Executive Officer (CEO), Chief Financial Officer (CFO), and heads of various departments such as commercial, medical affairs, and operations. The exact composition of the leadership team and the board can be found in the company's investor relations materials and SEC filings.
Top Products and Market Share
Key Offerings
- Nucynta / Nucynta ER: A centrally acting opioid analgesic for moderate to severe pain. Competitors include other opioid analgesics from companies like Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals, and generic manufacturers. Specific market share data is proprietary but it is a significant product for Assertio.
- Gabitril: An anti-epileptic drug used to treat partial seizures. Competitors include other anti-epileptic drugs from companies such as Pfizer (Neurontin), UCB (Keppra), and various generic options.
- Zipsor: A nonsteroidal anti-inflammatory drug (NSAID) used for acute pain. Competitors include a wide range of NSAIDs like ibuprofen (Advil, Motrin), naproxen (Aleve), and prescription NSAIDs from companies like Pfizer and Merck.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with a strong focus on research and development, marketing, and sales. The pain management and neurology segments are mature markets with established players and significant competition from both branded and generic products. There is a growing emphasis on non-opioid pain management alternatives and novel therapies for neurological disorders.
Positioning
Assertio Therapeutics is positioned as a specialty pharmaceutical company with a focus on commercializing its established portfolio of products. Its competitive advantages lie in its existing sales and marketing infrastructure, established relationships with healthcare providers, and a diversified product base within its niche markets. However, it faces challenges from generic competition and the ongoing scrutiny of opioid therapies.
Total Addressable Market (TAM)
The Total Addressable Market (TAM) for pain management and epilepsy is substantial, running into billions of dollars globally. Assertio Therapeutics targets specific segments within these markets with its products. Its positioning is focused on capturing a share of the existing market for its approved indications rather than pioneering entirely new therapeutic areas.
Upturn SWOT Analysis
Strengths
- Established product portfolio in key therapeutic areas.
- Experienced sales and marketing team.
- Diversified revenue streams from multiple products.
- Existing relationships with healthcare providers.
Weaknesses
- Reliance on existing products, with limited pipeline for new drug development.
- Vulnerability to generic competition.
- Potential regulatory and public perception challenges related to opioid products.
- Smaller market capitalization compared to larger pharmaceutical giants.
Opportunities
- Expansion into new geographic markets for existing products.
- Potential for strategic partnerships or acquisitions to enhance its portfolio.
- Leveraging its commercial expertise to launch new products (if acquired).
- Focusing on patient assistance programs to improve access and adherence.
Threats
- Increasing regulatory scrutiny and pricing pressures on pharmaceutical products, especially opioids.
- Intensifying competition from other pharmaceutical companies and generic manufacturers.
- Patent expirations leading to generic erosion.
- Changes in healthcare policies and reimbursement landscapes.
Competitors and Market Share
Key Competitors
- Mallinckrodt Pharmaceuticals (MNK)
- Endo Pharmaceuticals (ENDP)
- AbbVie Inc. (ABBV)
- Pfizer Inc. (PFE)
- Merck & Co., Inc. (MRK)
Competitive Landscape
Assertio Therapeutics competes in a fragmented market. Its advantages include a focused portfolio and established commercial infrastructure. However, it faces intense competition from larger pharmaceutical companies with broader product lines and R&D capabilities, as well as the pervasive threat of generic erosion. The company's ability to maintain market share depends on its commercial execution and the continued demand for its specific therapeutic offerings.
Growth Trajectory and Initiatives
Historical Growth: Assertio Therapeutics' historical growth has been influenced by its product portfolio performance, acquisitions, and market dynamics. The transition from Depomed to Assertio marked a strategic pivot, and subsequent growth has been tied to the success of its marketed products and any strategic initiatives undertaken. Revenue and profit have shown variability reflecting these factors.
Future Projections: Future growth projections for Assertio Therapeutics are typically based on analyst estimates, which consider factors such as expected product sales, market trends, competitive landscape, and any potential new product launches or strategic moves. These projections can be found in analyst reports and financial news.
Recent Initiatives: Recent initiatives may include optimizing its sales force, exploring new indications for existing products, or seeking strategic partnerships to expand its commercial reach or pipeline. The company has emphasized enhancing its commercial capabilities and exploring opportunities for value creation.
Summary
Assertio Therapeutics is a specialty pharmaceutical company with established products in pain management and neurology. Its strengths lie in its commercial capabilities and existing product portfolio, but it faces significant threats from generic competition and regulatory pressures, particularly for its opioid-based products. The company needs to focus on optimizing its current portfolio and exploring strategic opportunities to mitigate pipeline weaknesses and ensure long-term sustainable growth in a competitive market.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations
- SEC Filings (10-K, 10-Q)
- Financial News Outlets (e.g., Reuters, Bloomberg)
- Market Research Reports (general industry data)
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. Data accuracy is subject to the availability and timeliness of public disclosures. Users should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Assertio Therapeutics Inc
Exchange NASDAQ | Headquaters Lake Forest, IL, United States | ||
IPO Launch date 1997-11-05 | CEO & Director Mr. Mark L. Reisenauer | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 58 | Website https://www.assertiotx.com |
Full time employees 58 | Website https://www.assertiotx.com | ||
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.